CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05094804
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:30.060376+00:00
Published At: 2023-11-02T00:00:00+00:00
Record Updated At: 2023-11-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Tumor, Solid", "Malignant Neoplasm", "Metastatic Cancer", "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Melanoma", "Head and Neck Squamous Cell Carcinoma", "Leiomyosarcoma", "Liposarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-02"
protocolSection.identificationModule.nctId: "NCT05094804"
protocolSection.identificationModule.officialTitle: "A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.